Generic Uloric Availability
ULORIC (febuxostat - tablet;oral)
Manufacturer: TAKEDA PHARMS USA
Approval date: February 13, 2009
Strength(s): 40MG, 80MG [RLD]
Has a generic version of Uloric been approved?
No. There is currently no therapeutically equivalent version of Uloric available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uloric. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
2-arylthiazole derivatives and pharmaceutical composition thereof
Issued: March 25, 1997
Inventor(s): Kondo; Shiro & Fukushima; Hisashi & Hasegawa; Masaichi & Tsuchimoto; Masahiro & Nagata; Ikuo & Osada; Yoshio & Komoriya; Keiji & Yamaguchi; Hisao
Assignee(s): Teijin Limited
Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): ##STR1## wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.Patent expiration dates:
- March 25, 2019✓✓✓
- March 25, 2019
Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
Issued: May 1, 2001
Inventor(s): Matsumoto; Koichi & Watanabe; Kenzo & Hiramatsu; Toshiyuki & Kitamura; Mitsutaka
Assignee(s): Teijin Limited
The present invention provides a technique of selectively producing a desired polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid. The present invention also provides a method of producing various polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, which comprises crystallizing under the conditions defined by a specific temperature and a composition of a mixed solvent of methanol and water, and polymorphs obtained by the method. The present invention further provides a method of producing the other polymorphs or amorphous compounds by drying a specific polymorph under a reduced pressure with heating, and the other polymorphs or amorphous compounds obtained by the method.Patent expiration dates:
- June 18, 2019✓
- June 18, 2019
Solid preparation containing single crystal form
Issued: April 22, 2008
Inventor(s): Iwai; Michio & Nakamura; Kazuhiro & Dohi; Masahiko & Mochizuki; Hiroko & Mochizuki; Seiji
Assignee(s): Teijin Limited
There are provided a solid preparation containing a single crystal of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, an excipient and a disintegrating agent, and a method for producing the same.Patent expiration dates:
- March 8, 2024✓
- March 8, 2024
Methods for concomitant treatment of theophylline and febuxostat
Issued: February 12, 2013
Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.
Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.Patent expiration dates:
- September 8, 2031✓
- September 8, 2031
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- February 13, 2014 - NEW CHEMICAL ENTITY
- Uloric Consumer Information (Drugs.com)
- Uloric Consumer Information (Wolters Kluwer)
- Uloric Consumer Information (Cerner Multum)
- Uloric Advanced Consumer Information (Micromedex)
- Uloric AHFS DI Monographs (ASHP)
- Febuxostat Consumer Information (Wolters Kluwer)
- Febuxostat Consumer Information (Cerner Multum)
- Febuxostat Advanced Consumer Information (Micromedex)
- Febuxostat AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|